Opko Health inks $295M deal with Pfizer

December 15, 2014 3:51 PM

4 0

Opko Health inks $295M deal with Pfizer

Miami-based Opko Health will receive at least $295 million from Pfizer to develop Opko's growth hormone deficiency treatment.

Pfizer (NYSE: PFE) will have the exclusive license to sell the hGH-CTP treatment worldwide once it has been developed. The New York-based company is offering Opko Health (NYSE: OPK) an additional $275 million for clearing certain regulatory hurdles.

Read more

To category page